



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :

Oliver Schadt et al.

Serial No. : 10/551,905

Filed : October 5, 2005

For : PYRAZOLE COMPOUNDS

SUBMISSION OF PRIORITY DOCUMENT(S)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith is a certified copy of each of the below-identified document(s), benefit of priority of each of which is claimed under 35 U.S.C. § 119:

COUNTRY	APPLICATION NO.	FILING DATE
GERMANY	103 15 571.6	April 5, 2003

Acknowledgment of the receipt of the above document(s) is requested.

No fee is believed to be due in association with this filing, however, the Commissioner is hereby authorized to charge fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "HARRY B. SHUBIN".

Harry B. Shubin, Reg. No. 32,004
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3075

Date: May 22, 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the matter of an application for a German Patent

with the file reference 103 15 571.6
filed on 5 April 2003
in the name of Merck Patent GmbH, Darmstadt, Germany,

and in the matter of an application for a United States Patent.

I, Dr. Ashwood Stephen DRANE, B.Sc., Ph.D., BDÜ, translator to Steve Drane Translations Ltd. of Beechwood, Chivry, Tring, Hertfordshire, England, do solemnly and sincerely declare:

1. That I am a citizen of the United Kingdom of Great Britain and Northern Ireland.
2. That I am well acquainted with the German and English languages and am a competent translator thereof.
3. That the following is to the best of my knowledge and belief a true and correct translation of the above-referenced patent application and the Official Certificate attached thereto

Dated this 6th day of May 2008



Dr. Ashwood Stephen Drane



FEDERAL REPUBLIC OF GERMANY



Priority certificate regarding the filing of a patent application

File reference: 103 15 571.6

Date of filing: 5 April 2003

Applicant/proprietor: Merck Patent GmbH, 64293 Darmstadt/DE

Title: Pyrazole compounds

IPC: C 07 D, A 61 K, A 61 P

The attached pages are a correct and accurate reproduction of the original documents of this patent application.

Seal

Munich, 5 February 2004
German Patent and Trademark Office
On behalf of
The President

[signature]

**Merck Patent Gesellschaft
mit beschränkter Haftung**

64271 Darmstadt


Pyrazole compounds

- 1 -

Pyrazole compounds

The invention relates to compounds of the formula I

5



10

in which

R^2, R^4 denote H, A, Hal, cycloalkyl having 3 to 7 C atoms, CF_3 , NO_2 , CN , OCF_3 , OA, NHA, NA_2 , NH_2 ,

15

R^3, R^6 denote $(CH_2)_nHet$, $(CH_2)_nAr$,

20

R^1 denotes H or an organic radical, in particular $(CH_2)_nCO_2R^5$, $(CH_2)_nCOHHet$, CHO, $(CH_2)_nOR^5$, $(CH_2)_nHet$, $(CH_2)_nN(R^5)_2$, $CH=N-OA$, $CH_2CH=N-OA$, $(CH_2)_nNHOA$, $(CH_2)_n(R^5)Het$, $(CH_2)_nCH=N-Het$, $(CH_2)_nOCOR^5$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$, $(CH_2)_nN(R^5)C(R^5)COOR^5$, $(CH_2)_nN(R^5)CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2COOR^5$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH=CHCOOR^5$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$, $CH=CHCH_2OR^5$ or $(CH_2)_nN(R^5)Ar$,

R^5 denotes H or A

30

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

35

Het denotes an organic radical, in particular a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched

organic radical containing one or more hetero atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal,

Ar denotes an organic aromatic radical, in particular a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR⁵, OOCR⁵, COOR⁵, CON(R⁵)₂, CN, NO₂, NH₂, NHCOR⁵, CF₃, SO₂CH₃ or a ring-forming group -OCH₂O-, -O(CH₂)₂O- or -OC(CH₃)₂O-,

n denotes 0, 1, 2, 3, 4 or 5

and

Hal denotes F, Cl, Br or I

where, in the case that X has the meaning CH, R² and R⁴ do not simultaneously denote H,

and salts and solvates, enantiomers, racemates thereof and other mixtures of the enantiomers, in particular physiologically tolerated salts and solvates thereof.

The invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.

It has been found that the compounds of the formula I and salts and solvates thereof have very valuable pharmacological properties and are well tolerated.

The invention relates, in particular, to the compounds mentioned in the examples, which have the properties and potential uses of the compounds of the formula I that are outlined in the present application.

In particular, the compounds of the formula I according to the invention are suitable as ligands of 5 HT receptors, and consequently the compounds according to the invention, and salts and solvates, enantiomers and race-

mates thereof, in particular physiologically tolerated salts and solvates thereof, are suitable for the treatment and prophylaxis of diseases which can be influenced by the binding of the compounds of the formula I to 5 HT receptors.

5

Similar compounds are disclosed, for example, in DE 2201889, DE 2258033 or DE 2906252.

10

In particular, the compounds of the formula I according to the invention are suitable as ligands of 5 HT_{2A} and/or 5HT_{2C} receptors and can be used in human and veterinary medicine for the prophylaxis and treatment of various diseases of the central nervous system, such as, for example, schizophrenia, depression, dementia, dyskinesia, Parkinson's disease, Alzheimer's disease, Lewy bodies dementia, Huntington's, Tourette's syndrome, anxiety, learning and memory impairments, neurodegenerative diseases and other cognitive impairments, as well as nicotine dependence and pain.

15

The compounds of the formula I and/or physiologically acceptable salts or solvates thereof are particularly preferably used for the preparation of a medicament for the prophylaxis and/or treatment of psychoses, neurological disorders, amyotrophic lateral sclerosis, eating disorders, such as bulimia, anorexia nervosa, of premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder (OCD).

20

It has been found that the compounds of the formula I and physiologically acceptable salts and solvates thereof, while being well tolerated, have valuable pharmacological properties since they have actions on the central nervous system. The compounds have strong affinity to 5-HT_{2A} receptors, they furthermore exhibit 5-HT_{2A} receptor-antagonistic properties.

25

Preference is therefore given to the use of the compounds of the formula I and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT receptor-antagonistic action, in particular a 5-HT_{2A} receptor-antagonistic action.

30

35

- For in-vitro detection of the affinity to 5-HT_{2A} receptors, the following test (Example A1), for example, can be used. The 5-HT_{2A} receptors are exposed both to [³H]ketanserine (a substance known for its affinity to the receptor) and also to the test compound. The decrease in the affinity of
5 [³H]ketanserine to the receptor is an indication of the affinity of the test substance to the 5-HT_{2A} receptor. The detection is carried out analogously to the description by J.E. Leysen et al., Molecular Pharmacology, 1982, 21: 301-314, or as also described, for example, in EP 0320983.
- 10 The efficacy of the compounds according to the invention as 5-HT_{2A} receptor antagonists can be measured in vitro analogously to W. Feniuk et al., Mechanisms of 5-hydroxytryptamine-induced vasoconstriction, in: The Peripheral Actions of 5-Hydroxytryptamine, ed. Fozard JR, Oxford University Press, New York, 1989, p.110. Thus, the contractility of the rat tail artery caused by 5-hydroxytryptamine is mediated by 5-HT_{2A} receptors. For
15 the test system, vessel rings prepared from the ventral rat tail artery are subjected to perfusion in an organ bath containing an oxygen-saturated solution. By introducing increasing concentrations of 5-hydroxytryptamine into the solution, a response is obtained to the cumulative concentration of
20 5-HT. The test compound is then added to the organ bath in suitable concentrations, and a second concentration curve for 5-HT is measured. The strength of the test compound in shifting the 5-HT-induced concentration curve to higher 5-HT concentrations is a measure of the 5-HT_{2A} receptor-antagonistic property in vitro.
- 25 The 5-HT_{2A}-antagonistic property can be determined in vivo analogously to M.D.Serdar et al., Psychopharmacology, 1996, 128: 198-205.
- 30 The compounds of the formula I are therefore suitable both in veterinary and in human medicine for the treatment of functional disorders of the central nervous system and of inflammation. They can be used for the prophylaxis of and for combating the consequences of cerebral infarction phenomena (apoplexia cerebri), such as strokes and cerebral ischaemia, and
35 for the treatment of extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, for the acute and symptomatic therapy of Alzheimer's disease and for the treatment of amyotrophic lateral sclerosis. They are

likewise suitable as therapeutic agents for the treatment of brain and spinal cord traumas. In particular, however, they are suitable as medicament active ingredients for anxiolytics, antidepressants, antipsychotics, neuroleptics, antihypertonic and/or for positively influencing obsessive-compulsive disorder (OCD; for example WO 9524194), anxiety states and physiological changes associated with anxiety states, such as, for example, tachycardia, tremor or sweating (for example EP 319962), panic attacks, psychoses, schizophrenia, anorexia, delusional obsessions, agoraphobia, migraine, Alzheimer's disease, sleep disorders, including sleep apnoea, tardive dyskinesia, learning disorders, age-dependent memory disorders, eating disorders, such as bulimia, drugs misuse, such as, for example, of alcohol, opiates, nicotine, psychostimulants, such as, for example, cocaine or amphetamines (for example US 6004980), sexual dysfunctions, conditions of pain of all types and fibromyalgia (for example WO 9946245).

The compounds of the formula I are suitable for the treatment of extra-pyramidal side effects (EPS) in neuroleptic drug therapy. EPS is characterised by Parkinson's-like syndromes, acathisia and dystonic reactions (for example EP 337136). They are furthermore suitable for the treatment of anorexia nervosa, angina, Reynaud's, coronary vasospasms, in the prophylaxis of migraine (for example EP 208235), pain and neuralgia (for example EP 320983), for the treatment of Rett syndrome with autistic traits, of Asperger's syndrome, of autism and autistic disorders, in concentration deficit states, developmental disorders, hyperactivity states with mental underdevelopment and stereotypical behaviour states (for example WO 9524194).

They are furthermore suitable for the treatment of endocrine diseases, such as hyperprolactinaemia, furthermore in vasospasms, thrombotic diseases (for example WO 9946245), hypertension and gastrointestinal diseases.

They are furthermore suitable for the treatment of cardiovascular diseases and extrapyramidal symptoms, as described in WO 99/11641 on page 2, line 24-30.

The compounds according to the invention are furthermore suitable for reducing the intraocular pressure and for the treatment of glaucoma.

- 6 -

They are also suitable for the prophylaxis and treatment of poisoning phenomena on administration of ergovaline to animals.

The compounds are furthermore suitable for the treatment of diseases of the cardiovascular system (WO 99/11641, page 3, line 14-15). The com-

5 pounds according to the invention can also be employed together with other active ingredients in the treatment of schizophrenia. Suitable other active ingredients are the compounds mentioned in WO 99/11641 on page 13, line 20-26.

10 Other compounds which likewise exhibit 5-HT₂-antagonistic actions are described, for example, in EP 0320983.

WO 99/11641 describes phenylindole derivatives having 5-HT₂-antagonistic properties.


15 However, none of the above-mentioned documents describes the compounds of the formula I according to the invention or the use thereof as ligands of 5 HT receptors.

20 The compounds of the formula I can be employed as medicament active ingredients in human and veterinary medicine. They can furthermore be employed as intermediates for the preparation of further medicament active ingredients.

25 The invention accordingly relates to the compounds of the formula I and to the use thereof in human and animal medicine.

The present invention furthermore relates to a process for the preparation of compounds of the formula IA

30




IA

35

and salts and solvates thereof, which is characterised in that a compound of the formula II

5



10

or acid-addition salts thereof

in which

R⁴, R⁶ and X have the meanings indicated above,
is reacted with a compound of the formula III

15



20

in which


A and R³ have the meanings indicated above,

and/or in that a basic compound of the formula IA is converted into one of its salts by treatment with an acid.

25

The present invention furthermore relates to a process for the preparation of compounds of the formula IB


30



35

and salts and solvates thereof, which is characterised in that a compound of the formula II

- 8 -




5

or acid-addition salts thereof

in which

R^4 , R^6 and X have the meanings indicated above,
is reacted with a compound of the formula IV

10



15

in which


A and R^3 have the meanings indicated above,

and/or in that a basic compound of the formula IB is converted into one of its salts by treatment with an acid.

20

The compounds of the formulae IA and IB can be converted into the further compounds of the formula I by conventional methods. In particular, the compounds of the formula IA and IB can be converted, using reducing agents, such as, for example, lithium aluminium hydride, into the corresponding alcohols of the formulae IC and ID

25




30

35


- 9 -

5




which can be oxidised, for example using MnO_2 , to the compounds IE and IF.

10



15




20

The compounds of the formulae IE and IF can themselves be aminated by known processes using corresponding nucleophiles, such as, for example, nitrogen bases, in particular hydroxylamine, O-methylhydroxylamine, morpholine, piperidine, piperazine, N-methylpiperazine, 4-methylpiperazin-1-ylamine, pyrrolidine, pyrazolidine or imidazolidine, optionally in the presence of a reducing agent, such as sodium triacetoxyborohydride, or converted into the corresponding imines. Furthermore, the compounds of the formulae IE and IF can be converted, by Wittig reaction with methoxy-methyltriphenylphosphonium salts, into the corresponding enol ethers, which can be converted into the homologised aldehydes IG and IH

25


30

35



- 10 -

5



IH

by treatment with an acid. The compounds of the formula IG and IH can be converted into the further compounds of the formula I analogously to the compounds of the formulae IE and IF.

10

The invention likewise relates to the novel compounds of the formula II, III, IV and V.

15

Solvates of the compounds of the formula I are taken to mean adducts of inert solvent molecules onto the compounds of the formula I which form owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alcoholates.

20

Above and below, the radicals X, A, Ar, Het, n, R¹, R², R³, R⁴, R⁵ and R⁶ have the meanings indicated for the formula I, unless expressly stated otherwise.

X preferably denotes N.

25

R⁶ preferably stands for (CH₂)_nAr, in particular for Ar. R⁵ very particularly preferably denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl.

30

R³ preferably denotes (CH₂)_nHet or (CH₂)_nAr, in particular (CH₂)_nAr. R³ very particularly preferably denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl.

If R¹ denotes H, R² preferably has the meaning Hal, CN or alkyl having 1 to 7 C atoms, but in particular methyl, ethyl. If R² denotes H, R¹ preferably has the meaning (CH₂)_nCO₂R⁵, (CH₂)_nCO-Het, CHO, CH₂OR⁵, (CH₂)_n-Het, 5 (CH₂)_nN(R⁵)₂ or CH=N-OA, but in particular (CH₂)_nCO₂R⁵, (CH₂)_nCO-Het, CHO, CH=N-OA or (CH₂)_n-Het. R² particularly preferably denotes H.

Further preferred meanings of R¹ and R² arise from the examples.

10 R⁴ preferably denotes H, Hal, CN, A or NO₂, in particular H or Hal.

R⁵ preferably has the meaning A.

R⁶ preferably denotes (CH₂)_nAr, in particular Ar.











15 A preferably denotes alkyl, is preferably unbranched and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, preferably 1, 2, 3, 4, 5 or 6 C atoms, and preferably denotes methyl, ethyl, n-or propyl, furthermore preferably isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, but also n-pentyl, neopentyl, isopentyl 20 or n-hexyl. Particular preference is given to methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, n-hexyl or n-decyl.

A furthermore preferably has the meaning of the (CH₂)_mOCH₃ or (CH₂)_mC₂H₅ group, in which m denotes 2, 3, 4, 5 or 6, but in particular 2.















25 If A denotes alkenyl, it preferably stands for allyl, 2- or 3-butenyl, isobutenyl, sec-butenyl, furthermore preferably 4-pentenyl, isopentenyl or 5-hexenyl.

30 Het is preferably an aromatic and in particular saturated heterocyclic radical which is unsubstituted or substituted by A. Het preferably denotes 1-piperidyl, 1-piperazyl, 1-(4-methyl)piperazyl, 1-(4-ethyl)piperazinyl, 1-(4-cyclopentyl)piperazinyl, 4-methylpiperazin-1-ylamine, 1-pyrrolidinyl, 1-pyrazolidinyl 1-(2-methyl)pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)imidazolidinyl or 4-pyridyl, which may be unsubstituted or substituted by one or 35















more CN group, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl. Het furthermore preferably denotes a radical from the following table:

5		
10		
15		
20		
25		
30		
35		

- 13 -

		
5		
10		
15		
20		
25		
30		


- 14 -

		
5		
10		
15		
20		
25		
30		


- 15 -

	<chem>CCN1CCCCC1CO</chem>		<chem>CN1CCCC1</chem>
5	<chem>NN(C)CCN(C)CC</chem>		<chem>CCN(C)CCOC</chem>
10	<chem>CC(=O)C1CN(C)CC(O)C1</chem>		<chem>SC1=CNC(N)C1=O</chem>
15	<chem>CN(CC)c1ccccc1N2Cc3ccccc3N2</chem>		<chem>CC1(C)CC(=O)N(C)CC1</chem>
20	<chem>CC(C)N(C)C1=NC2=C=NC1=CN2</chem>		<chem>CN1CCCC1</chem>
25	<chem>CC(C)N1CCCC1</chem>		<chem>O=C1N(C)CC2=CC=C1C(=O)N2</chem>
30	<chem>C#CCNCC</chem>		<chem>CS(=O)(=O)N1CCCCC1</chem>
35	<chem>CN1CC2C1C3=CC=C2N3</chem>		<chem>CC1=NC2=C=NC1=CN2</chem>

- 16 -



Het particularly preferably denotes one of the following radicals:



Ar preferably denotes a phenyl radical which is unsubstituted or substituted by Hal, OH, CN, NO₂, NH₂, NHCOCH₃, COOCH₃, CONH₂ or CF₃. Ar is
35 preferably substituted in the 4- or 3-position.

n preferably denotes 0, 1 or 2, in particular 0 or 1.

Cycloalkyl preferably has 3-7 C atoms and preferably stands for cyclopropyl and cyclobutyl, furthermore preferably for cyclopentyl or cyclohexyl, furthermore also for cycloheptyl, particularly preferably cyclopentyl.

Hal preferably denotes F, Cl or Br, but also I.

If the compounds of the formula I has one or more chiral C atoms, the present invention relates to the enantiomers, diastereomers and mixtures thereof.

Throughout the invention, all radicals which occur more than once may be identical or different, i.e. are independent of one another.

Accordingly, the invention relates, in particular, to the compounds of the formula I in which at least one of the said radicals has one of the preferred meanings indicated above.

The compounds of the formula I and also the starting materials for their preparation are, in addition, prepared by methods known per se, as described in the literature (for example in the standard works, such as


Houben-Weyl, Methoden der organischen Chemie [Methods of Organic

Chemistry], Georg-Thieme-Verlag, Stuttgart), to be precise under reaction


conditions which are known and suitable for the said reactions. Use can

also be made here of variants known per se which are not mentioned here in greater detail.

The compound of the formula III is preferably obtained by reaction of compounds of the formula V



in which A has the meaning indicated above,
with compounds of the formula VI



in which R³ and A have the meaning indicated above,
under conditions known for such reactions.

The starting materials can, if desired, also be formed in situ by not isolating

5 them from the reaction mixture, but instead immediately converting them
further into the compounds of the formula I.

On the other hand, it is possible to carry out the reaction stepwise.

The starting materials of the formulae II, III and IV are generally known. If

10 they are not known, they can be prepared by methods known per se.

Specifically, the reactions of the compounds of the formula II with the com-
pounds of the formula III and the compounds of the formula IV are carried
out in the presence or absence of a preferably inert solvent at tempera-
15 tures between about -20 and about 150°, preferably between 20 and 100°.

Examples of suitable inert solvents are hydrocarbons, such as hexane,
petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons,
such as trichloroethylene, 1,2-dichloroethane, tetrachloromethane, chloro-
20 form or dichloromethane; alcohols, such as methanol, ethanol, isopropanol,
n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diiso-
propyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as eth-
ylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether
(diglyme); ketones, such as acetone or butanone; amides, such as acet-
25 amide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as
acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); nitro com-
pounds, such as nitromethane or nitrobenzene; esters, such as ethyl ace-
tate, or mixtures of the said solvents.

30 The pH necessary for the reaction can be set in accordance with pH values
selected for similar reactions of carbonyl compounds with amino com-
pounds. The pH is preferably pre-specified through the use of the particular
acid-addition salt, preferably a hydrogen halide addition salt, of the com-
35 pound of the formula II, i.e. there is no additional addition of a base or acid
to the reaction mixture. Preferred acid-addition salts are hydrochlorides or
hydrobromides

- A base of the formula I can be converted into the associated acid-addition salt using an acid, for example by reaction of equivalent amounts of the base and the acid in an inert solvent, such as ethanol, followed by evaporation. Suitable acids for this reaction are, in particular, those which give physiologically acceptable salts. Thus, it is possible to use inorganic acids, for example sulfuric acid, nitric acid, hydrohalic acids, such as hydrochloric acid or hydrobromic acid, phosphoric acids, such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, 5 araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, for example formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenemono- and -disulfonic acids, laurylsulfuric acid. Salts with physiologically unacceptable acids, 10 for example picrates, can be used for the isolation and/or purification of the compounds of the formula I.
- On the other hand, if desired, the free bases of the formula I can be liberated from their salts using bases (for example sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate). 15
- The invention relates, in particular, to compounds of the formula I and physiologically acceptable salts and solvates thereof as medicaments. 20
- The invention also relates to the compounds of the formula I and physiologically acceptable salts and solvates thereof as glycine transporter inhibitors. 25
- The invention furthermore relates to the use of the compounds of the formula I and/or physiologically acceptable salts and/or solvates thereof for the preparation of pharmaceutical compositions, in particular by non-chemical methods. In this case, they can be converted into a suitable dosage form together with at least one solid, liquid and/or semi-liquid excipient 30 35

or adjuvant and, if desired, in combination with one or more further active ingredients.

The invention furthermore relates to pharmaceutical compositions comprising at least one compound of the formula I and/or one of its physiologically acceptable salts and/or solvates.

These compositions can be used as medicaments in human or veterinary medicine. Suitable excipients are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical administration and do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatine, carbohydrates, such as lactose or starch, magnesium stearate, talc, Vaseline. Suitable for oral administration are, in particular, tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops, suitable for rectal administration are suppositories; suitable for parenteral administration are solutions, preferably oil-based or aqueous solutions, furthermore suspensions, emulsions or implants, suitable for topical application are ointments, creams or powders. The novel compounds may also be lyophilised and the resultant lyophilisates used, for example, for the preparation of injection preparations. The compositions indicated may be sterilised and/or comprise adjuvants, such as lubricants, preservatives, stabilisers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances, dyes, flavours and/or one or more further active ingredients, for example one or more vitamins.

In general, the substances according to the invention are preferably administered here in doses of between 1 and 500 mg, in particular between 5 and 100 mg, per dosage unit. The daily dose is preferably between about 30 0.02 and 10 mg/kg of body weight. However, the specific dose for each patient depends on a very wide variety of factors, for example on the efficacy of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and method of administration, on the excretion rate, medicament combination and severity of the particular disease to which the therapy applies. Oral administration is preferred.


Preferred compounds of the formula I have nanomolar affinity to the 5 HT2A receptors. Particularly preferred compounds of the formula I have low affinity to the 5 HT2C receptor. Very particularly preferred compounds of the formula I exhibit no significant glycine transporter activity.

5

Above and below, all temperatures are indicated in °C. In the following examples, "conventional work-up" means: water is added if necessary, the mixture is extracted with ethyl acetate or dichloromethane, the phases are separated, the organic phase is dried over sodium sulfate and evaporated, 10 and the product is purified by chromatography on silica gel and/or by crystallisation.

Example 1

15




20

130 g of monoethyl malonate potassium salt are suspended in 2 l of ethyl acetate in a 6 l three-necked flask provided with stirrer, condenser, thermometer, dropping funnel and drying tube, 127 ml of triethylamine and 25 82.4 g of magnesium chloride (anhydrous) are added with cooling and stirring at 0°C, and the mixture is slowly warmed to 35-40°C. Stirring is continued at this temperature for 6 h, the mixture is again cooled to 0°C, and a solution of 50 ml of furan-2-carbonyl chloride in 1 l of ethyl acetate is added dropwise over the course of 15 minutes with cooling and stirring at 0°C. 30 Stirring is continued overnight at RT, then 1.2 l of 13% hydrochloric acid are added dropwise with cooling and stirring, and the ethyl acetate phase is separated off. Conventional work-up gives the product 2 as slightly yellowish liquid. (b.p. 85°C/0.6-0.5 mbar).

35

- 22 -


Example 2



10 5 g of ethyl 2-furoylacetate are dissolved in 100 ml of THF, abs., in a 250 ml flask provided with magnetic stirrer, condenser and drying tube, 7.4 ml of N,N-dimethylformamide dimethyl acetal are added, and the mixture is stirred under reflux for 6 h. The reaction solution was then stripped off to give the residue 6.38 g (100%), giving 3.

15

Example 3




30 4.49 g of the beta-keto ester 3 are dissolved in 90 ml of abs. ethanol in a 250 ml one-necked flask provided with magnetic stirrer, condenser and drying tube, 4.2 g of 4-bromophenylhydrazinium chloride are added, and the mixture is stirred under reflux overnight. Conventional work-up gives 4.

35

- 23 -


Example 4

5



10

15

45

2.00 g of the aryl bromide 4 and 0.203 g of [1,1'-bis(diphenylphosphino)-
20 ferrocene)palladium(II) dichloride are dissolved successively in 80 ml of di-
methoxyethane, 1.40 g of 4-fluorophenylboronic acid are added, and a
solution of Na₂CO₃ in water (5.87 g in 25 ml) is subsequently added. The
reaction solution is stirred overnight at RT. For work-up, the reaction batch
is partitioned between diethyl ether and water. Conventional work-up gives
5.


25

30

35

- 24 -

Example 5



20 1.60 g of the ester 5 are initially introduced in THF, cooled to about 5 to 0°C, and 4.3 ml of a 1 M solution of LiAlH₄ in THF is subsequently slowly added dropwise. When the addition is complete, stirring is continued overnight at room temperature. Conventional work-up gives 6 crystalline solid.


25

30

35

- 25 -

Example 6



1.4 g of the alcohol 6 is dissolved in a mixture of 10 ml of THF and 40 ml of dichloromethane. 2.62 g of manganese dioxide are subsequently added, and the reaction batch is stirred overnight at RT. Conventional work-up gives the product 7 as crystalline solid.

25

30

35

Example 7



5

10

15

20

25

78

36 µl of CH₃COOH are added to a mixture of 200 mg of the aldehyde 7, 103 mg of ethylpiperazine, 3.6 ml of 1,2-dichloroethane and 1.8 ml of THF. The mixture is stirred at room temperature for 3 h. 0.23 g of NaB(OAc)₃H are subsequently added, and stirring is continued for 16 h..

Conventional work-up gives 1-ethyl-4-[1-(4'-fluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]piperazine dihydrochloride 8 as colourless solid.

30

The following compounds of the formula I are obtained analogously using the corresponding precursors:

35

Examples 8 – 51:

-
- (8) 1-[1-(3,4'-Difluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-yl-methyl]-4-methylpiperazine
5 (9) 1-[1-(3,4'-Difluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-yl-methyl]-4-ethylpiperazine
(10) 1-[1-(3,4'-Difluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-yl-methyl]pyrrolidin-3-ol
10 (11) 1-[1-(3,4'-Difluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-yl-methyl]piperazine
(12) [1-(3,4'-Difluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-yl-methyl]dimethylamine
15 (13) [1-(3,4'-Difluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-yl-methyl]ethylmethylamine
(14) [1-(3,4'-Difluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-yl-methyl]methyl-(1-methylpyrrolidin-3-yl)amine
(15) 1-[1-(2,4'-Difluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-yl-methyl]-4-methylpiperazine
20 (16) [1-(2,4'-Difluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-yl-methyl]ethylmethylamine
(17) 1-[1-(4'-Fluorobiphenyl-4-yl)-3-methyl-5-phenyl-1H-pyrazol-4-yl-methyl]-4-methylpiperazine
(18) Ethyl-[1-(4'-fluorobiphenyl-4-yl)-3-methyl-5-phenyl-1H-pyrazol-4-yl-methyl]methylamine
25 (19) (1-Biphenyl-4-yl-3-methyl-5-phenyl-1H-pyrazol-4-yl)acetic acid ethyl ester
(20) 2-(1-Biphenyl-4-yl-3-methyl-5-phenyl-1H-pyrazol-4-yl)ethanol
30 (21) 1-{5-[2-(4'-Fluorobiphenyl-4-yl)-5-methyl-2H-pyrazol-3-yl]furan-2-yl-methyl}-4-methylpiperazine
(22) 1-Ethyl-4-{5-[2-(4'-fluorobiphenyl-4-yl)-5-methyl-2H-pyrazol-3-yl]-furan-2-ylmethyl}piperazine
(23) Ethyl-{5-[2-(4'-fluorobiphenyl-4-yl)-5-methyl-2H-pyrazol-3-yl]furan-2-ylmethyl}methylamine
35 (24) 1-{5-[2-(4'-Fluorobiphenyl-4-yl)-5-methyl-2H-pyrazol-3-yl]furan-2-yl-methyl}pyrrolidin-3-ol

- (25) 1-[1-(4'-Fluorobiphenyl-4-yl)-3,5-dimethyl-1H-pyrazol-4-ylmethyl]-4-methylpiperazine
(26) 1-Ethyl-4-[1-(4'-fluorobiphenyl-4-yl)-3,5-dimethyl-1H-pyrazol-4-ylmethyl]piperazine
5 (27) Ethyl-[1-(4'-fluorobiphenyl-4-yl)-3,5-dimethyl-1H-pyrazol-4-ylmethyl]methylamine
(28) 1-[1-(4'-Fluorobiphenyl-4-yl)-5-methyl-1H-pyrazol-4-ylmethyl]-4-methylpiperazine
10 (29) 1-Ethyl-4-[1-(4'-fluorobiphenyl-4-yl)-5-methyl-1H-pyrazol-4-ylmethyl]piperazine
(30) 1-[1-(4'-Fluorobiphenyl-4-yl)-5-methyl-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol
15 (31) Ethyl-[1-(4'-fluorobiphenyl-4-yl)-5-methyl-1H-pyrazol-4-ylmethyl]methylamine
(32) 1-[1-(4'-Fluorobiphenyl-4-yl)-3,5-dimethyl-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol
(33) 1-[1-(4'-Fluorobiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol
20 (34) 1-[1-(4'-Fluorobiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]-4-methylpiperazine
(35) 1-Ethyl-4-[1-(4'-fluorobiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]piperazine
(36) 1-[1-(4'-Fluoro-2-methylbiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]-4-methylpiperazine
25 (37) 1-Ethyl-4-[1-(4'-fluoro-2-methylbiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]piperazine
(38) Ethyl-[1-(4'-fluoro-2-methylbiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]methylamine
(39) 1-[1-(4'-Fluoro-2-methylbiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol
30 (40) 1-[1-(2-Chloro-4'-fluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]-4-methylpiperazine
(41) 1-[1-(2-Chloro-4'-fluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]-4-ethylpiperazine
35 (42) 1-[1-(2-Chloro-4'-fluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol
(43) [1-(2-Chloro-4'-fluorobiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-yl-

- methyl]ethylmethylamine
- (44) 1-[1-(4'-Fluoro-3-methylbiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-yl-methyl]-4-methylpiperazine
- (45) 1-Ethyl-4-[1-(4'-fluoro-3-methylbiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]piperazine
- 5 (46) 1-[1-(4'-Fluoro-3-methylbiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol
- (47) Ethyl-[1-(4'-fluoro-3-methylbiphenyl-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]methylamine
- 10 (48) 1-[5-Furan-2-yl-1-(2,6,4'-trifluorobiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]-4-methylpiperazine
- (49) 1-Ethyl-4-[5-furan-2-yl-1-(2,6,4'-trifluorobiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]piperazine
- (50) 1-[5-Furan-2-yl-1-(2,6,4'-trifluorobiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol
- 15 (51) Ethyl-[5-furan-2-yl-1-(2,6,4'-trifluorobiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]methylamine

The examples below relate to pharmaceutical compositions:

20

Example A: Injection vials

A solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate in 3 l of bidistilled water is adjusted to pH 6.5

25

using 2N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilised under sterile conditions and sealed under sterile conditions.

Each injection vial contains 5 mg of active ingredient.

Example B: Suppositories

30

A mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soya lecithin and 1400 g of cocoa butter, poured into moulds and allowed to cool. Each suppository contains 20 mg of active ingredient.

Example C: Solution

35

5 A solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of $\text{NaH}_2\text{PO}_4 \cdot 2 \text{ H}_2\text{O}$, 28.48 g of $\text{Na}_2\text{HPO}_4 \cdot 12 \text{ H}_2\text{O}$ and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to 6.8, and the solution is made up to 1 l and sterilised by irradiation. This solution can be used in the form of eye drops.

Example D: Ointment

10 500 mg of an active ingredient of the formula I are mixed with 99.5 g of Vaseline under aseptic conditions.

Example E: Tablets

15 A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed in a conventional manner to give tablets in such a way that each tablet contains 10 mg of active ingredient.

20 **Example F: Coated tablets**

Tablets are pressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.

25 **Example G: Capsules**

30 2 kg of active ingredient of the formula I are introduced in a conventional manner into hard gelatine capsules in such a way that each capsule contains 20 mg of the active ingredient.

Example H: Ampoules

35 A solution of 1 kg of active ingredient of the formula I in 60 l of bidistilled water is sterile filtered, transferred into ampoules, lyophilised under sterile

- 31 -

conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient.

Example I: Inhalation spray

5

14 g of active ingredient of the formula I are dissolved in 10 l of isotonic NaCl solution, and the solution is transferred into commercially available spray containers with pump mechanism. The solution can be sprayed into the mouth or nose. One spray shot (about 0.1 ml) corresponds to a dose of 10 about 0.14 mg.

15

20

25


30

35

Patent Claims

1. Compounds of the formula I

5



10

in which

R^2, R^4 denote H, A, Hal, cycloalkyl having 3 to 7 C atoms, CF_3 , NO_2 , CN , OCF_3 , OA, NHA, NA_2 , NH_2 ,

15

R^3, R^6 denote $(CH_2)_nHet$, $(CH_2)_nAr$,

20

R^1 denotes H or an organic radical, in particular
 $(CH_2)_nCO_2R^5$, $(CH_2)_nCOHet$, CHO, $(CH_2)_nOR^5$, $(CH_2)_nHet$,
 $(CH_2)_nN(R^5)_2$, $CH=N-OA$, $CH_2CH=N-OA$, $(CH_2)_nNHOA$,
 $(CH_2)_n(R^5)Het$, $(CH_2)_nCH=N-Het$, $(CH_2)_nOCOR^5$,
 $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$,
 $(CH_2)_nN(R^5)C(R^5)COOR^5$, $(CH_2)_nN(R^5)CH_2COHet$,
 $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$,
 $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2COOR^5$,
 $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH=CHCOOR^5$,
 $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$, $CH=CHCH_2OR^5$
or $(CH_2)_nN(R^5)Ar$,

25

30

R^5 denotes H or A


A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

35


- Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical containing one or more hetero atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal,
- 5 Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR⁵, OOCR⁵, COOR⁵, CON(R⁵)₂, CN, NO₂, NH₂, NHCOR⁵, CF₃ or SO₂CH₃,
- 10 n denotes 0, 1, 2, 3, 4 or 5
- and
- 15 Hal denotes F, Cl, Br or I
- where, in the case that X has the meaning CH, R² and R⁴ do not simultaneously denote H,
- 20 and salts and solvates, enantiomers, racemates thereof and other mixtures of the enantiomers, in particular physiologically tolerated salts and solvates thereof.
- 25 2. Compounds of the formula I according to Claim 1, in which R⁶ denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl.
- 30 3. Compounds of the formula I according to one or more of the preceding claims, in which R⁴ denotes H, Hal, CN, A or NO₂.
4. Compounds of the formula I according to one or more of the preceding claims, in which R² denotes H or alkyl.
- 35

5. Compounds of the formula I according to one or more of the preceding claims, in which R³ denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl.
- 5
10 6. Compounds of the formula I according to one or more of the preceding claims, in which X has the meaning N.
7. Compounds of the formulae IA, IB, IC, ID, IE and IF:


15




20





25



30




35




in which

15 R^3 , R^4 , R^6 and X have the meanings indicated in Claim 1.

8. Process for the preparation of compounds of the formula IA



in which R^3 , R^4 , R^6 , X and A have the meaning indicated in Claim 1
25 and salts and solvates thereof, which is characterised in that a com-
pound of the formula II




or acid-addition salts thereof

in which

35 R^4 , R^6 and X have the meanings indicated in Claim 1,
is reacted with a compound of the formula III

5



III


10

in which

A and R³ have the meanings indicated in Claim 1,and/or in that a basic compound of the formula IA is converted into
one of its salts by treatment with an acid.

9. Process for the preparation of compounds of the formula IB

15




IB

20

in which R³, R⁴, R⁶, X and A have the meaning indicated in Claim 1
and salts and solvates thereof, which is characterised in that a com-
pound of the formula II

25



II


30

or acid-addition salts thereof

in which

R⁴, R⁶ and X have the meanings indicated in Claim 1,
is reacted with a compound of the formula IV

35




- 5 in which
A and R³ have the meanings indicated in Claim 1,
and/or in that a basic compound of the formula IB is converted into
one of its salts by treatment with an acid.
- 10 10. Compounds of the formula I according to one or more of Claims 1 to
6 and physiologically acceptable salts and solvates thereof as medi-
caments.
- 15 11. Use of the compounds of the formula I according to one or more of
Claims 1 to 6 , and salts and solvates thereof, for the preparation of a
medicament for the treatment and prophylaxis of diseases which can
be influenced by the binding of the compounds of the formula I to
5 HT receptors.
- 20 12. Use of compounds of the formula I according to one or more of
Claims 1 to 6 and/or physiologically acceptable salts and solvates
thereof for the preparation of a medicament having a 5-HT receptor-
antagonistic action.
- 25 13. Use of compounds of the formula I according to one or more of
Claims 1 to 6 and/or physiologically acceptable salts and solvates
thereof for the preparation of a medicament having a 5-HT2A recep-
tor-antagonistic action.
- 30 14. Pharmaceutical composition characterised by a content of at least
one compound of the formula I according to one or more of Claims 1
to 6 and/or one of its physiologically acceptable salts and/or one of its
solvates.
- 35 15. Process for the preparation of pharmaceutical compositions, charac-
terised in that a compound of the formula I according to Claim 1

and/or one of its physiological acceptable salts and/or one of its solvates is converted into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

- 5 16. Use of compounds of the formula according to one or more of Claims
1 to 6 and/or physiologically acceptable salts or solvates thereof for
the preparation of a medicament for the prophylaxis and/or treatment
of psychoses, neurological disorders, amyotrophic lateral sclerosis,
eating disorders, such as bulimia, anorexia nervosa, of premenstrual
10 syndrome and/or for positively influencing obsessive-compulsive dis-
order (OCD).

- 15 17. Compounds of the formula I in which Het denotes one of the following
radicals:



30


35

- 39 -

Abstract

Compounds of the formula I

5



10

and salts and solvates thereof, in which X, R¹, R², R³, R⁴, R⁵ and R⁶ have the meanings indicated in Claim 1, are suitable as ligands of 5 HT receptors.

15

20

25

30

35